GNH USA

Europe — EMA

Opzelura (Ruxolitinib)

GNH USA supplies Opzelura (Ruxolitinib), a Janus kinase inhibitor for atopic dermatitis and vitiligo. Request a quote for global supply.

Ruxolitinib

Request sourcing

1
Pack/s

What is Ruxolitinib?

Ruxolitinib, the active ingredient in Opzelura, is a Janus kinase (JAK) inhibitor presented as a cream for topical use. It treats atopic dermatitis and vitiligo in patients requiring immunomodulatory therapy.

GNH USA supplies Opzelura as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution. Opzelura is manufactured under GMP conditions and is approved for use in the European Union. It is available only by prescription and is intended for adult and pediatric patients as determined by a healthcare professional.

What is Ruxolitinib used for?

Opzelura (ruxolitinib) is a topical Janus kinase inhibitor used to manage inflammatory skin disorders.

- Atopic dermatitis: reduces inflammation and pruritus in moderate‑to‑severe disease. - Vitiligo: promotes repigmentation by modulating the immune response in affected skin. - Chronic inflammatory skin conditions: may be considered under clinical supervision where JAK pathway involvement is identified.

What are the side effects of Ruxolitinib?

Opzelura may cause local and systemic adverse reactions.

Common Side Effects: - Application site irritation or burning. - Redness or erythema at the site of application. - Dry or flaky skin. - Pruritus or itching.

Serious or Rare Side Effects: - Secondary skin infection at the treated area. - Severe allergic reactions, including angioedema. - Systemic immunosuppression leading to opportunistic infections. - Potential increased risk of malignancy with long‑term use. - Cardiovascular events such as thrombosis in susceptible individuals.

What precautions apply to Ruxolitinib?

Before using Opzelura, consider the following safety measures.

- Pregnancy: safety not established; avoid unless benefits outweigh risks. - Breastfeeding: unknown; discuss with a healthcare professional. - Concomitant immunosuppressants: monitor for increased infection risk. - Use on damaged or infected skin: avoid application to compromised skin. - Known hypersensitivity to ruxolitinib or formulation components: do not use. - Store at room temperature: keep in the original tube, protect from light and moisture.

What does Ruxolitinib interact with?

Opzelura can interact with other medicines; review the following.

Major Interactions (Avoid): - Systemic JAK inhibitors: additive immunosuppression may be hazardous. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise ruxolitinib levels. - Live attenuated vaccines: contraindicated during therapy.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin): monitor for increased exposure. - Topical corticosteroids: may increase local irritation; use with caution.

Frequently asked questions

What conditions is Opzelura used to treat?+
Opzelura is a prescription‑only topical cream containing ruxolitinib that is approved for the treatment of moderate‑to‑severe atopic dermatitis and for the management of vitiligo. In both conditions the medication works by reducing the inflammatory response in the skin, helping to control itching, redness, and lesion spread.
How does ruxolitinib work in Opzelura?+
Ruxolitinib blocks the activity of Janus kinase 1 and 2 (JAK1/JAK2), key enzymes in the cytokine signaling cascade. By inhibiting these kinases, the drug prevents the activation of STAT proteins, which reduces the production of inflammatory mediators in the skin and thereby diminishes the symptoms of inflammatory dermatoses.
What is the usual dose of Opzelura?+
The exact amount of Opzelura to apply is determined by the prescribing clinician based on disease severity, affected body surface area, and patient age. Typically, a thin layer is spread over the affected skin once or twice daily, but the prescriber will provide specific instructions tailored to each individual.
Is Opzelura safe to use during pregnancy or while breastfeeding?+
Safety data for Opzelura in pregnancy and lactation are limited. The product should be avoided unless the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or nursing should discuss alternative options with their healthcare provider.
How do I order Opzelura from GNH USA?+
To request Opzelura, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA supplies hospitals, pharmacies and procurement teams across international markets. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements), and assist with import documentation.
How does Opzelura compare with other treatments for atopic dermatitis?+
Opzelura offers a targeted, topical JAK‑inhibition approach, which differs from traditional topical steroids or calcineurin inhibitors that act more broadly on inflammation. Compared with systemic JAK inhibitors, Opzelura provides localized activity with lower systemic exposure, potentially reducing systemic side‑effects while still delivering effective control of moderate‑to‑severe disease.
How should Opzelura be stored and handled?+
Opzelura should be stored at room temperature, preferably below 25 °C, in its original container. Keep the tube tightly closed, protect it from direct sunlight, and avoid exposure to moisture. Do not freeze the product. If the cream appears discoloured or contaminated, discard it and obtain a new supply.
How is Opzelura applied?+
Before application, wash and gently pat the affected skin dry. Apply a thin, even layer of the cream to the designated area(s) and rub gently until fully absorbed. Follow the prescriber’s frequency instructions, usually once or twice daily, and wash your hands after each application unless the hands are being treated.
What are the most serious risks associated with Opzelura?+
Serious risks include secondary skin infections, severe allergic reactions such as angioedema, systemic immunosuppression that may predispose to opportunistic infections, and a potential increased risk of malignancy with prolonged use. Patients should be monitored regularly for signs of infection, unusual skin changes, or systemic symptoms and report them promptly.
Who should not use Opzelura?+
Opzelura is contraindicated in individuals with a known hypersensitivity to ruxolitinib or any component of the cream. It should also be avoided in patients with active skin infections, those receiving live attenuated vaccines, and anyone using systemic JAK inhibitors unless specifically directed by a specialist. Pregnant or breastfeeding women should only use it if clearly advised by their physician.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Ruxolitinib
Route
Cutaneous Use
Manufacturer
Incyte Biosciences Distribution B.V.
Origin
EU

Related products

Jakavi

Jakavi

Ruxolitinib

Novartis Europharm Limited
EU
Jakavi

Jakavi

Ruxolitinib

Novartis Europharm Limited
EU
Jakavi

Jakavi

Ruxolitinib

Novartis Europharm Limited
EU
Jakavi

Jakavi

Ruxolitinib

Novartis Europharm Limited
EU